Search Within

Romel Somwar

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (42)
  2. Meeting Abstract (41)
  3. Editorial (1)
  4. Research Letter (1)
Groups
  1. Department of Pathology and Laboratory Medicine (85)
  2. GSK Faculty (85)
  3. Human Oncology and Pathogenesis Program (85)
  4. Sloan Kettering Institute Postdocs (85)
  5. Tow Center for Developmental Oncology (TCDO) (85)
  6. Department of Medicine (53)

More Groups

People
  1. Marc Ladanyi (85)
  2. Alexander Drilon (37)
  3. Elisa De Stanchina (33)
  4. Marissa Mattar (30)
  5. Gregory Riely (26)
  6. Inna Khodos (25)

More People

Years
  1. 2025 (2)
  2. 2024 (10)
  3. 2023 (5)
  4. 2022 (15)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Journal of Thoracic Oncology (20)
  2. Clinical Cancer Research (15)
  3. Journal of Clinical Oncology (9)
  4. Cancer Research (7)
  5. Cancer Discovery (3)
  6. JCO Precision Oncology (3)

More Publications

Publishers
  1. American Association for Cancer Research (27)
  2. Elsevier Inc. (22)
  3. American Society of Clinical Oncology (13)
  4. Nature Publishing Group (5)
  5. Oxford University Press (4)
  6. Nature Research (3)

More Publishers

Results (85)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers
    Journal Article

    Vojnic, M.; Kubota, D.; Kurzatkowski, C.; Offin, M.; Suzawa, K.; Benayed, R.; Schoenfeld, A. J.; Plodkowski, A. J.; Poirier, J. T.; Rudin, C. M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Lu, D.; Kurzatkowski, C.; Vojnic, M.; Smith, R. S.; Sabari, J. K.; Tai, H.; Mattar, M.; Khodos, I.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Acquired BRAF fusions as a mechanism of resistance to EGFR therapy
    Meeting Abstract

    Vojnic, M.; Kurzatkowski, C.; Kubota, D.; Suzawa, K.; Liu, Z.; Mattar, M.; Khodos, I.; Poirier, J. T.; de Stanchina, E.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers
    Journal Article

    Offin, M.; Somwar, R.; Rekhtman, N.; Benayed, R.; Chang, J. C.; Plodkowski, A.; Lui, A. J. W.; Eng, J.; Rosenblum, M.; Li, B. T.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma
    Journal Article

    Davare, M. A.; Henderson, J. J.; Agarwal, A.; Wagner, J. P.; Iyer, S. R.; Shah, N.; Woltjer, R.; Somwar, R.; Gilheeney, S. W.; DeCarvalo, A.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
    Journal Article

    Yu, H. A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M. G.; Hellmann, M. D.; Li, B. T.; Somwar, R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • RASA1 and NF1 are preferentially co-mutated and define a distinct genetic subset of smoking-associated non–small cell lung carcinomas sensitive to MEK inhibition
    Journal Article

    Hayashi, T.; Desmeules, P.; Smith, R. S.; Drilon, A.; Somwar, R.; Ladanyi, M.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers
    Journal Article

    Drilon, A.; Somwar, R.; Mangatt, B. P.; Edgren, H.; Desmeules, P.; Ruusulehto, A.; Smith, R. S.; Delasos, L.; Vojnic, M.; Plodkowski, A. J.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save